Argenica Therapeutics (AGN) Short Interest
Argenica Therapeutics (ASX:AGN) had 0.01% of shares reported as short positions as of 29 June 2026, representing 15,198 shares. Argenica Therapeutics operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Argenica Therapeutics
Argenica Therapeutics Limited is a biotechnology company focused on developing novel neuroprotective treatments aimed at reducing brain damage following strokes and other severe brain injuries. Positioned as an innovator in the neuroprotection field, the company leverages cutting-edge research to create therapies that can potentially transform patient outcomes.
Short position
Argenica Therapeutics (ASX:AGN) has 0.01% of its shares on issue reported as short positions as of 29 June 2026, or about 15,198 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. AGN is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 34, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4AGN intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Argenica Therapeutics
Latest AGN news
All news- Argenica Therapeutics Limited (ASX:AGN) Share Price Falls 5.56% as Stock Trades Within Daily Range - Kalkine
googlenews
- Notification of cessation of securities - AGN
asx
- Argenica Therapeutics Ltd (ASX: AGN) Share Price Update: Stock Rises as Health Care Sector Closes Lower - Kalkine
googlenews
- Investor Presentation - Techknow Conference
asx
- Quarterly Activities/Appendix 4C Cash Flow Report
asx
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss AGN
Start a research thread or post the first pulse update